A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Placebo
Drug: AZD9742

Study type

Interventional

Funder types

Industry

Identifiers

NCT01064388
D2690C00002

Details and patient eligibility

About

The purpose of this study is to determine the safety, tolerability and blood levels of AZD9742 after daily dosing for 14 days.

Enrollment

36 patients

Sex

All

Ages

23 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

BMI between 19-30

Exclusion criteria

  • Positive Fecal Occult Blood Test
  • Prescriptions that inhibit liver function
  • Received flu/H1N1 vaccine within 2 weeks before first dose

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

36 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: AZD9742
2
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems